HOME >> BIOLOGY >> NEWS
Cell Genesys reports antitumor activity in Phase I/II GVAX lung cancer vaccine trial

SAN FRANCISCO, Calif., May 13, 2001Cell Genesys, Inc. (Nasdaq: CEGE) today reported interim clinical data from its multicenter Phase I/II GVAX lung cancer vaccine trial which demonstrates objective evidence of antitumor activity including a major response rate of 18 percent in patients with advanced non small-cell lung cancer who have failed chemotherapy and/or radiation therapy. These data were presented on behalf of the GVAX Lung Cancer Clinical Investigators by John Nemunaitis, M.D. of U.S. Oncology at the American Society of Clinical Oncology (ASCO) Meeting in San Francisco, Calif. The presentation was one of 17 selected for ASCOs Official Press Program from the more than 3,300 submitted to the meeting.

The interim clinical trial data includes results on 30 currently evaluable patients with advanced or early-stage lung cancer. Of 22 patients with advanced-stage lung cancer, three patients, two of whom had failed chemotherapy and one who failed radiation therapy, showed a complete disappearance of metastatic tumors following treatment with GVAX lung cancer vaccine. One other patient who failed radiation and chemotherapy had partial (greater than 50 percent) reduction in his tumor. In addition to these major responses, four patients currently have stable (non-progressive) disease. All of these responses are continuing with a median follow-up time of approximately five months. In addition to the responses in patients with advanced disease, seven of eight patients with early-stage lung cancer who received GVAX vaccine following surgery, currently remain free of disease with a median follow-up time of seven months.

We are very encouraged by what we have seen to date with GVAX lung cancer vaccine, particularly with respect to the major tumor responses in patients with metastatic lung cancer who have failed chemotherapy, stated Dr. Nemunaitis. These findings are all the more noteworthy given that lung cancer patients who fail chemotherapy have little c
'"/>

Contact: Todd Ringler
tringler@fkhealth.com
617-761-6791
Feinstein Kean Healthcare
12-May-2001


Page: 1 2 3 4

Related biology news :

1. Cell Genesys reports long term survival data in Phase II trial of GVAX prostate cancer vaccine
2. UroGenesys researchers discover new target antigen for prostate cancers
3. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
4. Scientists question reports of massive ant supercolonies in California and Europe
5. Survey reports fall in stem cell transplants for breast cancer
6. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
7. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
8. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
9. Measles on the rise as vaccinations fall in the UK, Science study reports
10. WCS biologist George Schaller reports surprising increase in Tibets wildlife
11. Clinical study reports findings of combination therapy with DOXIL

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... , ... KICVentures announced today its plans to host an event ... ASC Conference in Chicago on Thursday, June 13th at 6:30 pm. The event will ... the 3rd floor Ticino Hospitality room in space #74T. , The event will feature ...
(Date:6/11/2019)... Ind. (PRWEB) , ... June 10, 2019 , ... Improved ... in the July 2019 issue of AAPS PharmSciTech. The article was published online on ... of Improved Pharma, along with Xiaoming Sean Chen of Purdue University. , The ...
(Date:6/6/2019)... ... June 05, 2019 , ... ... the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition ... anatomic pathology platform that provides services to more than one dozen hospitals and ...
Breaking Biology News(10 mins):
(Date:5/15/2019)... , ... May 16, 2019 , ... ... mixtures. As a result, food and beverage products rely on these ingredients to ... more natural sounding label declarations. This paradigm shift triggers food formulators to seek ...
(Date:5/8/2019)... , ... May 07, 2019 , ... Standing at 16.2 hands, Atlas is on the ... in a drill team and barrel racing, among other activities. When loping around a ... He went from being a busy horse to only being able to walk. Fortunately ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, the ... ffERG/Photopic Negative Response vision test, a new full field electroretinography (ffERG) protocol ... that 6.3 million Americans will have glaucoma, with black Americans having the highest ...
(Date:5/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading experts ... so be sure to register today to save your place! Participate in the discussion ... upcoming webinars: , CLINICAL TRIALS , May 7 – Oncology Clinical Trials – The ...
Breaking Biology Technology:
Cached News: